VISEN Pharmaceuticals Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-216.79	-182.24	-249.57	-288.97
Depreciation & Amortization	2.46	3.95	6.15	6.67
Other Amortization	0.51	0.51	0.85	0.72
Loss (Gain) From Sale of Assets	-0.72	-	0.24	0.09
Stock-Based Compensation	44.55	32.77	-12.27	93.51
Other Operating Activities	3.08	2.48	67.12	-0.77
Change in Accounts Payable	-1.32	1.21	-12.08	4.44
Change in Unearned Revenue	-	-2.9	-	-
Change in Other Net Operating Assets	-12.01	3.36	-71.75	-62.25
Operating Cash Flow	-180.24	-140.86	-271.31	-246.55
Capital Expenditures	-0.12	-0.12	-0.52	-1.48
Sale (Purchase) of Intangibles	9.24	-	-	-0.28
Investing Cash Flow	9.12	-0.12	-0.52	-1.77
Long-Term Debt Repaid	-	-3.09	-4.95	-5.78
Net Debt Issued (Repaid)	-2.31	-3.09	-4.95	-5.78
Other Financing Activities	-20.37	-	-2.01	-2.17
Financing Cash Flow	700.54	-3.09	-6.95	-7.95
Foreign Exchange Rate Adjustments	0.17	-0.13	0.11	0.07
Net Cash Flow	529.59	-144.2	-278.68	-256.2
Free Cash Flow	-180.36	-140.98	-271.83	-248.03
Free Cash Flow Margin	-21445.66%	-5076.52%	-	-
Free Cash Flow Per Share	-1.86	-1.51	-2.90	-
Levered Free Cash Flow	-	-63.57	-67.66	-
Unlevered Free Cash Flow	-	-63.47	-67.46	-
Change in Working Capital	-13.33	1.66	-83.83	-57.81

Source: S&P Global Market Intelligence. Standard template. Financial Sources.